←
Compounding Lab6,617 posts
Compounding Lab avatar

Compounding Lab

@CompoundingLab

Chief DCF manipulator, market investigator and fundamental chartist. ACCA, CISI. Dynamic asset allocation. Not financial advice.

◷ Joined January 2016▧ 1,465 Photos and videos
Compounding Lab avatar
Compounding Lab@CompoundingLab·Sep 13

My Free Substack subscription offer: * Full valuation workings with traceable assumptions and the math behind every figure * Access to my own portfolio performance and holdings * Discuss my thoughts on the market * Share my knowledge with subscribers who wish to learn investment analysis * Daily undervalued stock charts with analysts' consensus Link: compoundinglab.substack.com/…

Compounding Lab avatar
Compounding Lab@CompoundingLab·8h

$CSCO DCF VALUATION MODEL Cisco’s founders were pushed out just six months after its IPO. A decade later, it briefly became the world’s most valuable company. Today, Cisco has stabilized its margins, and Wall Street is celebrating again. But there's a problem: the market may be pricing in far more than the company can deliver. My DCF tells a different story. KEY ASSUMPTIONS: Explicit average 5Y/5Y growth @ 9.7%/5.3% Long-term growth in perpetuity @ 2.5% Adj. EBITDA Margin 28.3% -> 32.30% WACC @ 9.0% Adj. EBITDA exit multiple of 11.6 Tax rate 21% - in line with OECD’s Pillar 2 “Global Minimum Tax” The input that drives reinvestment is the Sales-to-Capital ratio = 3.32

Post attachment
Compounding Lab avatar
Compounding Lab@CompoundingLab·10h

For some reason these people believe that market is stupid but they are always clever! Wake up dude, never heard about markets being semi-efficient? Or you think if you outperformed on a 1y basis that gives you right to disrespect the crowd?

$OSCR sell off is stupid.. Healthcare is selling off broadly because the new rule proposed by the Centers for Medicare and Medicaid Services (CMS) can result in substantial clawbacks of payments previously made to Medicare insurers. $OSCR has no medicare business.

Post attachment
Compounding Lab avatar
Compounding Lab@CompoundingLab·17h

$AVGO DCF VALUATION MODEL (REVISED) Is the AI boom hiding a valuation trap, or a massive opportunity? By FY2028, AI could account for 80%+ of revenue for Broadcom. But that future depends on hyperscalers keeping their custom-chip spending spree alive. Ahead of December earnings, I ran a TTM-based DCF (excluding any possible future acquisitions). Here's what the market may be missing. KEY ASSUMPTIONS: * Explicit average 5Y/5Y growth @ 39%/11.3% * Long-term growth in perpetuity @ 2.6% * Adj. EBITDA Margin constant 58% * WACC @ 11.1% * Adj. EBITDA exit multiple of 11.9 * Tax rate 18% * The input that drives reinvestment is the Sales-to-Capital ratio = 2.1

Post attachment
Compounding Lab avatar
Compounding Lab@CompoundingLab·Nov 17

Correlation between S&P 500 companies' 5-year stock returns and average annual revenue growth rate. If you pull out companies with > 20% revenue growth and calculate this portfolio CAGR return, the equal-weight portfolio delivered a 24.97% CAGR. The question is, what is the chance of selecting those stocks if you are in Nov 2021?

Post attachment
Compounding Lab avatar
Compounding Lab@CompoundingLab·Nov 15

I’ve heard many investors discuss $PLTR. At 100 price-to-2026 earnings, some say it’s cheap, while others argue it’s expensive relative to its peers. First of all, never underestimate the market- even a high P/E can be justified! As we know, it all depends on the forecasted drivers of value: ROIC and growth, and ultimately, how much cash the company will generate. To see what the market is currently expecting, I built a model using M. Mauboussin’s market-implied CAP framework, also known as a reverse DCF. Here are the assumptions currently embedded in the stock price. * Explicit average growth @ 41%, declining gradually from 53% -> 28% * Long-term growth in perpetuity @ 2.5% * Adj. EBITDA Margin improvement 46% -> 49.4% * WACC @ 12.6% * Tax rate 8% -> 23% due to short-term tax shields effect * The input that drives reinvestment is the most recent Sales to Capital ratio = 7.58. Noticeably, Palantir grew revenue with almost no additional capital required in the past. Interpretation: A 10-year explicit forecast is enough to show the assumptions required for the stock to justify its current price of 168. To decide whether the stock is attractive, compare your own assumptions with those already reflected in the share price. For example, if you believe revenue can continue growing at 20% per year after Year 11, rather than slowing to the broader economy’s 2.5% growth rate, the stock may be a buy for you, all else being equal.

Post attachment
Compounding Lab avatar
Compounding Lab@CompoundingLab·Nov 14

Jensen Huang left. One way or another, the law of large numbers prevailed again. $NVDA had grown too large, and sustaining its high historical growth rates would likely have made the company larger than an entire economy. That could never happen. In this article, I explore listed companies with strong compounding potential, led by founders who share some of Mr. Huang’s qualities: energy, a disruptive approach, an innovative mindset, and solid management skills. In other words, I look at founder-led stocks that could become the next Nvidia-style success story. I screened for founders with characteristics similar to Jensen Huang around 2001, when Nvidia was still an emerging semiconductor company: - Technical vision: They understand their technology, not just the financial statements. - Disruptive ambition: They are trying to transform large industries. - Exceptional execution: They can convert technology into commercial products and scale a business. - Founder mentality: They are personally committed to a long-term vision. - 10× stock potential: Their companies have sufficient room to grow relative to their current valuations. The final criterion is particularly demanding. Therefore, we should distinguish an exceptional founder from an exceptional stock investment. A great entrepreneur can build a hugely successful company while shareholders earn disappointing returns if they pay too much initially. My highest-conviction founder shortlist is here. Rankings reflect my qualitative assessment of founder quality, execution and long-term optionality, not predicted stock returns. 1. Angus Pacala - Ouster (OUST), $2.7B MC: Closest to young Jensen's technical-founder profile 2. Waleed Hassanein - TransMedics (TMDX), $3.2B: Innovative with proven commercial execution 3. JoeBen Bevirt - Joby Aviation (JOBY), $5.4B: Highly ambitious engineering founder 4. Will Marshall - Planet Labs ($PL), ~$5B: Building planetary-scale data infrastructure 5. Andrew Dudum - Hims & Hers ($HIMS), $4.6B: Exceptional consumer-platform ambition and growth 6. Luis von Ahn - Duolingo ($DUOL), $7.4B: Proven product inventor and consumer-tech leader 7. Chris Urmson - Aurora Innovation ($AUR), $8.8B: Outstanding autonomous-driving engineering pedigree 8. Steve Altemus - Intuitive Machines ($LUNR), $3.0B: Strong space-engineering execution 9. Adam Goldstein - Archer Aviation ($ACHR), $3.4B: Aggressive aerospace commercialization 10. Soroush Salehian - Aeva ($AEVA), $0.8B: High-risk, differentiated deep-tech bet 11. Paul Gu - Upstart ($UPST), $1.9B: Young technical cofounder and current CEO 12. Keyvan Mohajer - SoundHound AI ($SOUN), $1.8B: Independent voice-AI innovator; weaker moat visibility These are potential 10-baggers, not stocks I necessarily expect to multiply tenfold in the base case. Some have a real chance to become much larger businesses but are still speculative investments. Why the top five stand out 1. Angus Pacala - Ouster ($OUST) Physical AI, robotics and LiDAR. Pacala was 38 in 2026, approximately Jensen Huang's age in 2001. He's an engineering founder building a foundational sensing technology for robots and autonomous systems. Ouster recorded $59M in Q3 revenue and its 15th consecutive quarter of product revenue growth. 10X path: Become a dominant sensing and perception platform across industrial robotics, autonomous mobility and infrastructure, reaching around $27B in market value. Main concern: Hardware competition and whether sensing technology can sustain a high-margin moat. 2. Waleed Hassanein - TransMedics ($TMDX) Medical technology, organ preservation. Hassanein combines deep medical expertise with the ability to build an operational ecosystem around proprietary technology. TransMedics is changing how transplant organs are preserved and transported. Q3 revenue increased 41% to $203 million, and the company generated $17.1 million in net income. Expansion into kidney transplantation and Europe provides additional runway. 10X path: Build a global organ transplant infrastructure leader worth approximately $32B. Main concern: Market size, regulatory adoption and how much of the transplant value chain the business can capture. 3. JoeBen Bevirt - Joby Aviation ($JOBY) Electric aviation, robotics and autonomy. Bevirt has previously founded engineering businesses, including Velocity11, which was acquired by Agilent. He has spent years designing an entirely new aircraft architecture. In Q3 2026, Joby reported 17 aircraft in production and approximately $2.2 billion in cash and short-term investments, while advancing its FAA certification program. 10X path: Become a leading global electric aviation manufacturer and service operator, worth over $50 billion. Main concern: Certification, mass manufacturing, economics per aircraft and substantial capital requirements. 4. Will Marshall - Planet Labs (PL) Satellites, geospatial intelligence and AI data. Marshall has built a satellite-imaging platform with the ambition to observe the entire Earth continuously. This has applications across intelligence, defense, agriculture and other industries. Planet reported 58% year-over-year growth in its fiscal Q2 2027, with revenue of $116M and strong momentum in government satellite programs. 10X path: Move beyond imagery into a critical global real-time intelligence and analytics platform. Main concern: Competition, expensive satellite infrastructure and capturing enough software-like economics to justify a 50B valuation. 5. Andrew Dudum - Hims & Hers (HIMS) Consumer healthcare platform. Dudum is more of a product, brand and distribution visionary than a semiconductor-style inventor. His ambition is to make Hims & Hers a comprehensive digital healthcare relationship rather than a collection of individual treatments. Q3 revenue grew 49% to roughly $890 million, with nearly 2.8 million subscribers. 10X path: Become a global consumer healthcare platform valued around $46 billion, supported by expanding treatment categories and improving long-term profitability. Main concern: Regulation, drug availability, customer-acquisition costs and competition. Three founders who may be even more Jensen-like, but whose stocks already have a higher valuation hurdle: * Peter Beck. Rocket Lab ($RKLB), ~$40B MC. One of the strongest engineering-founder analogues. Q3 2026 revenue grew 73%, but a 10× outcome now requires $400B of market capitalization. * Andrew Feldman. Cerebras Systems ($CBRS), ~$23B MC before its latest earnings reaction. A direct challenger to the conventional GPU architecture. Its wafer-scale computing technology is differentiated, and Q3 cloud revenue grew rapidly. * Jitendra Mohan Astera Labs ($ALAB), ~$39B MC. Technically sophisticated founder with strong operating execution. Q3 revenue reached $585M, up 154% year over year. However, considerable future growth is already reflected in the valuation. Not financial advice. DYOR.

Post attachment
Compounding Lab avatar
Compounding Lab@CompoundingLab·Nov 10

Fine, but no one cares. Because Coreweave doesn't have moat. Why I don't see a sustainable moat: 1. Intense competition. CoreWeave competes against Microsoft, Amazon, Google, Oracle, Nebius and other GPU cloud providers. Its infrastructure is not fundamentally impossible to replicate. 2. Limited pricing power. Access to Nvidia GPUs is valuable today, but competitors can purchase similar hardware. GPU rental prices could decline as supply expands. 3. Enormous capital requirements. AI accelerators become technologically obsolete relatively quickly. Maintaining competitiveness requires continuous reinvestment. 4. Limited customer lock-in. Long-term contracts provide revenue visibility, but customers can eventually migrate workloads or develop internal infrastructure. 5. Questionable sustainable ROIC. Morningstar's analysis highlights CoreWeave's difficulty generating returns on invested capital exceeding its cost of capital. At the same time, CoreWeave's advantages should not be underestimated: *Strong relationships with Nvidia and major AI customers. *Expertise in deploying large GPU clusters. *Access to substantial contracted electricity capacity. *Long-term customer contracts providing revenue visibility. Despite that extraordinary revenue growth, the company expects $37–39 billion in capital expenditures during 2026. Interest expense alone reached $846 million in Q3. I see CoreWeave as a company with a potentially strong temporary competitive advantage, rather than a durable economic moat. Next 3–5 years: CoreWeave could benefit enormously from the AI infrastructure shortage. Next 10–15 years: I'm much less confident that it can defend attractive margins and earn ROIC consistently above WACC. Final classification: No moat, with the potential to develop a narrow moat.

JUST IN: $CRWV says customers are now funding up to 100% of their contract values upfront.

Post attachment
Capitalism Lab avatar
⟳ Compounding Lab retweeted
Capitalism Lab@CapitalismLab·Nov 7

Ever wondered why your company is profitable, but its cash balance isn’t growing? Capitalism Lab 13.0.00 Beta introduces a Cash Flow Statement that shows where your company’s cash comes from and where it goes.

Post attachment
Lumen avatar
⟳ Compounding Lab retweeted
Lumen@LumenX_·Nov 6

Dear Lord, bless my Mom.

Post attachment
Compounding Lab avatar
Compounding Lab@CompoundingLab·Nov 7

Chiao Cyprus. Apart from etoro summit, I had a chance to meet some good old teammates from Ukraine. We are all over the world now. Upwards and onwards!

Post attachment